$6.62
1.93% yesterday
Nasdaq, Sep 23, 10:00 pm CET

Champions Oncology, Inc. Stock price

$6.62
-0.44 6.23% 1M
-3.18 32.45% 6M
-1.95 22.75% YTD
+2.04 44.54% 1Y
-1.28 16.20% 3Y
-2.28 25.62% 5Y
+0.12 1.85% 10Y
+6.08 1,125.93% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.13 1.93%

Key metrics

Basic
Market capitalization
$91.3m
Enterprise Value
$81.1m
Net debt
positive
Cash
$10.3m
Shares outstanding
13.8m
Valuation (TTM | estimate)
P/E
33.1 | 29.5
P/S
1.6 | 1.5
EV/Sales
1.4 | 1.3
EV/FCF
11.3
P/B
26.0
Financial Health
Equity Ratio
11.7%
Return on Equity
124.6%
ROCE
38.3%
ROIC
325.9%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$56.9m | $62.2m
EBITDA
$4.6m | $3.1m
EBIT
$3.0m | $-254.0k
Net Income
$3.0m | $3.1m
Free Cash Flow
$7.2m
Growth (TTM | estimate)
Revenue
10.1% | 9.3%
EBITDA
383.2% | -51.6%
EBIT
186.6% | -105.2%
Net Income
186.8% | -34.3%
Free Cash Flow
460.0%
Margin (TTM | estimate)
Gross
48.5%
EBITDA
8.0% | 5.1%
EBIT
5.3%
Net
5.2% | 5.0%
Free Cash Flow
12.7%
More
EPS
$0.2
FCF per Share
$0.5
Short interest
1.3%
Employees
210
Rev per Employee
$270.0k
Show more

Is Champions Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Champions Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Champions Oncology, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Champions Oncology, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Champions Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '25
+/-
%
57 57
10% 10%
100%
- Direct Costs 29 29
2% 2%
52%
28 28
21% 21%
48%
- Selling and Administrative Expenses 17 17
3% 3%
30%
- Research and Development Expense 7.45 7.45
9% 9%
13%
4.56 4.56
383% 383%
8%
- Depreciation and Amortization 1.55 1.55
17% 17%
3%
EBIT (Operating Income) EBIT 3.01 3.01
187% 187%
5%
Net Profit 2.95 2.95
187% 187%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Champions Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Champions Oncology, Inc. Stock News

Neutral
Seeking Alpha
8 days ago
Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2026 Earnings Call September 15, 2025 4:30 PM EDT Company Participants Robert Brainin - CEO & Director David Miller - Chief Financial Officer Conference Call Participants George Marema - Pareto Ventures Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Greetings. Welcome to the Champions Oncology First Quarter Fis...
Neutral
Accesswire
8 days ago
This release contains a headline correction from the previous publication. Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2...
Neutral
Accesswire
8 days ago
Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025. First Quarter and Recent Highlights: Total revenue of $14 million Adju...
More Champions Oncology, Inc. News

Company Profile

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Head office United States
CEO Ronnie Morris
Employees 210
Founded 1985
Website championsoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today